Dexcom (NSDQ:DXCM) said this week that it acquired TypeZero Technologies and its personalized diabetes management solutions. The financial details of the transaction were not disclosed. Dexcom plans to support the first commercial launch of an automated insulin delivery system using TypeZero’s inControl algorithm next year. Get the full story at our sister site, Drug Delivery Business News.
Senseonics (NYSE:SENS) said today that it inked a collaboration with TypeZero Technologies and Roche (OTC:RHHBY) Diabetes Care to develop an automated insulin delivery system. The deal is part of an NIH-funded effort to test artificial pancreas systems. The trial is slated to integrate Senseonic’s Eversense glucose monitor, TypeZero’s inControl AP algorithms and Roche’s Accu-Chek Insight insulin pump. The software automatically […]
Medical device companies are close to achieving the holy grail of diabetes treatment: a combined glucose sensor, control algorithm and insulin infusion device that effectively acts as an “artificial pancreas.” We explain more in the newest video from editors at MassDevice’s sister publication Medical Design & Outsourcing. (And for a deeper dive, check out our recent […]
Senseonics (NYSE:SENS) said yesterday that it inked a non-exclusive R&D license agreement with TypeZero Technologies to develop artificial pancreas and decision support systems for its Eversense continuous glucose monitor. The companies plan to integrate glucose readings from the Eversense system with TypeZero’s inControl artificial pancreas algorithms to regulate insulin delivery through a user’s insulin pump. […]
Tandem Diabetes Care (NSDQ:TNDM) said today it inked a license agreement with TypeZero Technologies to integrate TypeZero’s artificial pancreas into Tandem’s next-gen t:slim insulin pump. TypeZero’s artificial pancreas technology includes algorithms developed off of initial research conducted at the University of Virginia, and the company said it has been used in more than 28 clinical studies including […]
A device developed at the University of Virginia School of Medicine which automatically monitors and regulates blood-sugar level in type 1 diabetes patients is slated to undergo 2 final clinical trials beginning early this year. UVA said it was hopeful that the long-term clinical trials would pave the way for FDA clearance of the ‘artificial pancreas’ […]